Literature DB >> 31215389

High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics.

Eyaldeva C Vijayakumar1, Lokesh Kumar Bhatt1, Kedar S Prabhavalkar1.   

Abstract

High mobility group box-1 (HMGB1) mainly belongs to the non-histone DNA-binding protein. It has been studied as a nuclear protein that is present in eukaryotic cells. From the HMG family, HMGB1 protein has been focused particularly for its pivotal role in several pathologies. HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation. Modulation of HMGB1 levels in the human body provides a way in the management of these diseases. Various strategies, such as HMGB1-receptor antagonists, inhibitors of its signalling pathway, antibodies, RNA inhibitors, vagus nerve stimulation etc. have been used to inhibit expression, release or activity of HMGB1. This review encompasses the role of HMGB1 in various pathologies and discusses its therapeutic potential in these pathologies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  High mobility group box-1; cancer; cytokine mediator; inflammatory disease; sepsis; therapeutics.

Year:  2019        PMID： 31215389     DOI： 10.2174/1389450120666190618125100

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  20 in total

1.  Restoration of calcium-induced differentiation potential and tight junction formation in HaCaT keratinocytes by functional attenuation of overexpressed high mobility group box-1 protein.

Authors:  Fumika Tanaka; Minori Uda; Yuina Hirose; Yohei Hirai
Journal:  Cytotechnology       Date:  2020-01-08       Impact factor: 2.058

Review 2.  Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs.

Authors:  Tapan Behl; Eshita Sharma; Aayush Sehgal; Ishnoor Kaur; Arun Kumar; Rashmi Arora; Giridhari Pal; Munish Kakkar; Ravinder Kumar; Simona Bungau
Journal:  Mol Biol Rep       Date:  2021-01-21       Impact factor: 2.316

Review 3.  Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective.

Authors:  Shu Wang; Yu-Guang Guan; Yan-Hua Zhu; Min-Zhong Wang
Journal:  World J Psychiatry       Date:  2022-06-19

Review 4.  The Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention.

Authors:  Sara Merlo; Simona Federica Spampinato; Grazia Ilaria Caruso; Maria Angela Sortino
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 5.  Fibroblast Growth Factors in the Management of Acute Kidney Injury Following Ischemia-Reperfusion.

Authors:  Lian-Cheng Deng; Tahereh Alinejad; Saverio Bellusci; Jin-San Zhang
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

6.  lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma.

Authors:  Xuewei Zhu; Li Liu; Yang Wang; Jianan Cong; Zhang Lin; Yongsen Wang; Qi Liu; Leiming Wang; Ben Yang; Tao Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 7.  Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.

Authors:  Walter Gottlieb Land
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 8.  High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives.

Authors:  Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Giovanni Pecorini; Raffaele Landolfi; Andrea Flex
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

9.  HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.

Authors:  Lulu Liu; Jingjing Zhang; Xianning Zhang; Panpan Cheng; Lei Liu; Qian Huang; Haihui Liu; Saisai Ren; Peng Wei; Cuiling Wang; Cuiyun Dou; Lulu Chen; Xin Liu; Hao Zhang; Mingtai Chen
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

10.  Anti-High Mobility Group Box 1 Neutralizing-Antibody Ameliorates Dextran Sodium Sulfate Colitis in Mice.

Authors:  Liping Chen; Junhua Li; Zhenghao Ye; Binghua Sun; Lu Wang; Yu Chen; Jian Han; Meiping Yu; Ying Wang; Qi Zhou; Ursula Seidler; De'an Tian; Fang Xiao
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.